Search global stocks & ETFs...Ctrl K

Learn Mode

RPRX - Royalty Pharma PLC

50

$50.44

$0.24 (0.478%)

At close: 5/5/26, 8:00 PM

Score

3.57/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

RPRX

Valuation Score

View as %

Stock Unlock

YTD

Max

Stock Profile

Market Cap

$29.10B

Industry

Pharmaceuticals

EPS (TTM)

$1.38

P/E (TTM)

37.75

Div & Yield

$0.94 (1.86%)

FCF Payout Ratio

68.47%

P/S (TTM)

12.24

P/B

4.49

Diluted Shares

557.56M

Ex-Dividend

2026-05-15

Next Earnings

05-06

Forward P/E

9.33

Payout Ratio

70.35%

P/FCF (TTM)

36.74

FCF Yield

2.72%

Earnings Yield

2.65%

52 Week Range

Score Card

Explore Scores Tab

3.57

Good

Royalty Pharma PLC has grown revenue at 5.06% over the past year, which suggests sales are increasing. Also, it has more cash than current liabilities meaning it has enough cash to handle all its debts within the next year, if it wanted to.

Valuation Model

Key Score

4.00

Good

Management

5.00

Very Good

Growth

3.00

Average

Profitability

4.00

Good

Fin. Health

1.00

Very Bad

Dividends

4.00

Good

Analyst

4.00

Good

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

1 new filing was in the last 7 days

Filter Form Types

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-30 17:54:06

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-04-28 17:00:16

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-04-13 09:53:04

Form ARS

Unknown Form Type

Filed on 2026-04-10 16:11:40

Form DEFA14A

Additional definitive proxy soliciting materials

Filed on 2026-04-10 16:11:03

Form DEF 14A

Also known as a 'definitive proxy statement', is a required filing when a shareholder vote is required

Filed on 2026-04-10 16:10:09

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-02 17:58:57

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-04-01 16:55:58

Form 13F-NT

Unknown Form Type

Filed on 2026-04-01 16:41:34

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-31 16:09:28

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-25 17:05:22

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-03-23 16:43:18

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-04-25

High:

$66.15

31.1%

Avg:

$54.05

7.1%

Low:

$46.46

-7.9%

(% change is relative to the current stock price: $50.44)

Analyst Recommendations

Go to Analyst Tab

4.19

Good

31%

Strong Buy (5)

56%

Buy (9)

13%

Hold (2)

Sell (0)

Strong Sell (0)

About

Website
https://www.royaltypharma.com/
Address
110 East 59th Street, New York City NEW YORK, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=1802768

Royalty Pharma Plc engages in the provision of drug development services. The company is headquartered in New York City, New York and currently employs 100 full-time employees. The company went IPO on 2020-06-16. The company collaborates with innovators from academic institutions, research hospitals and non-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. The company funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, and Gilead’s Trodelvy, among others, and 20 development-stage product candidates.

IPO Date

2020-06-16

Industry

Pharmaceuticals

Total Employees

100

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Pharmaceuticals

GICS Sub

Pharmaceuticals

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences

RPRX - Royalty Pharma PLC

50

$50.44

$0.24 (0.478%)

3.57/5

Stock Unlock

Stock Profile

Score Card

Good

Insider Transactions

Market News

Form 4

Filed on 2026-04-30 17:54:06

Form 144

Filed on 2026-04-28 17:00:16

Form 8-K

Filed on 2026-04-13 09:53:04

Form ARS

Filed on 2026-04-10 16:11:40

Form DEFA14A

Filed on 2026-04-10 16:11:03

Form DEF 14A

Filed on 2026-04-10 16:10:09

Form 4

Filed on 2026-04-02 17:58:57

Form 144

Filed on 2026-04-01 16:55:58

Form 13F-NT

Filed on 2026-04-01 16:41:34

Form 4

Filed on 2026-03-31 16:09:28

Form 4

Filed on 2026-03-25 17:05:22

Form 144

Filed on 2026-03-23 16:43:18

Financials

Price Targets

31.1%

7.1%

-7.9%

Analyst Recommendations

About

Similar Stocks